# Innovaderm (Canada)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/innovaderm-canada/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 74 |
| Citations | 24,463 |
| City | Montreal |
| Country | Canada |
| Description | Innovaderm (Canada) is a research organisation in Montreal, Canada. OpenAlex records 481 works and 24,463 citations for it. 1 researchers list it as their most recent affiliation. |
| Homepage | http://www.innovaderm.ca/ |
| OpenAlex ID | https://openalex.org/I4210138799 |
| Region | Quebec |
| Researchers | 1 |
| ROR ID | https://ror.org/0486db050 |
| Type | company |
| Works | 481 |

## University papers

- [Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis](https://scholariq.org/papers/dupilumab-progressively-improves-systemic-and-cutaneous-abnormalities-in/)
- [Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial](https://scholariq.org/papers/topical-tofacitinib-for-atopic-dermatitis-a-phase-scp-ii-scp-a-randomized-trial/)
- [Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial](https://scholariq.org/papers/efficacy-and-safety-of-oral-alitretinoin-9-cis-retinoic-acid-in-patients-with/)
- [Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials](https://scholariq.org/papers/baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-and-inadequate/)
- [A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis](https://scholariq.org/papers/a-phase-2-trial-of-guselkumab-versus-adalimumab-for-plaque-psoriasis/)
- [Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study](https://scholariq.org/papers/dupilumab-shows-long-term-safety-and-efficacy-in-patients-with-moderate-to/)
- [IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis](https://scholariq.org/papers/il-4r-blockade-by-dupilumab-decreases-staphylococcus-aureus-colonization-and/)
- [Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-multiple-dupilumab-dose-regimens-after-initial-successful/)
- [Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)](https://scholariq.org/papers/baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-results-from-a/)

## University researchers

- [Robert Bissonnette](https://scholariq.org/researchers/robert-bissonnette/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.